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doi:10.101Autologous Peripheral Blood Stem Cell Transplantation
in Children with Refractory or Relapsed Lymphoma:
Results of Children’s Oncology Group Study A5962
Richard E. Harris,1 Amanda M. Termuhlen,2 Lynette M. Smith,3 James Lynch,3
Michael M. Henry,4 Sherrie L. Perkins,5 Thomas G. Gross,2 Phyllis Warkentin,6
Adrianna Vlachos,7 Lauren Harrison,8 Mitchell S. Cairo8This prospective study was designed to determine the safety and efficacy of cyclophosphamide, BCNU, and
etoposide (CBV) conditioning and autologous peripheral blood stem cell transplant (PBSCT) in children with
relapsed or refractory Hodgkin and non-Hodgkin lymphoma (HL and NHL). Patients achieving complete re-
mission (CR) or partial remission (PR) after 2 to 4 courses of reinduction underwent a granulocyte-colony
stimulating factor (G-CSF) mobilized PBSC apheresis with a target collection dose of 5  106 CD341/kg.
Those eligible to proceed received autologous PBSCT after CBV (7200 mg/m2, 450-300 mg/m2, 2400
mg/m2). Forty-three of 69 patients (30/39 HL, 13/30 NHL) achieved a CR/PR after reinduction. Thirty-
eight patients (28 HL, 10 NHL) underwent PBSCT. All initial 6 patients who received BCNU at 450
mg/m2 experienced grade III or IV pulmonary toxicity compared to none of the subsequent 32 receiving
300 mg/m2 (P\.0001). The probability of overall survival (OS) at 3 years for all patients is 51% and for trans-
planted patients is 64%. The 3-year event-free survival (EFS) is 38% (45% for HL; 30%NHL). The 3-year EFS in
transplanted patients is 66% (65%HL; 70%NHL). Initial duration of remission of$12 versus\12months was
associated with a significant increase in OS (3 years OS 70% versus 34%) (P5 .003). BCNU at 300 mg/m2 in
a CBV regimen prior to PBSCT is well tolerated in relapsed or refractory pediatric lymphoma patients. A
short duration (\12months) of initial remission is associatedwith a poorer prognosis. Last, a high percentage
of patients achieving a CR/PR after reinduction therapy can be salvaged with CBV and autologlous PBSCT.
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The prognosis for children with newly diagnosed
lymphomas has significantly improved over the last 25
years. The survival rate for patients with localized and
disseminated non-Hodgkin lymphoma (NHL) is over
95% and over 80%, respectively, for most subtypes
[1-11]. However, the prognosis for refractory or
recurrent NHL in children and adolescents remains
poor. Patients enrolled in the Children’s Cancer
Group (CCG) 551 that subsequently relapsed had
a 12% 5-year overall survival (OS) [12]. The 5-year
OS for relapsed NHL patients using dexamethasone,
etoposide, cisplatin, high-dose cytarabine, andL-aspar-
aginase (DECAL) was 30% [13]. Children diagnosed
with Stage I or II HL experience a long-term event-
free survival (EFS) .90% [14,15]. Patients with
advanced stage or “B” symptoms at presentation have
long-term EFS rates of over 80% [16]. As in NHL,
children with relapsed or refractory Hodgkin lym-
phoma (HL) have a poor prognosis [17,18]. The 5-
year OS is 31% for children with HL reinduced with249
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23%, respectively, with cytosine arabinoside, cisplatin,
and etoposide (APE) [17].
Inadultswith lymphoma, autologous stemcell trans-
plant (autoSCT) results in 4 to 10 year OS rates of 42%
to 70% [19-22]. Factors associatedwith a poor prognosis
in adults with lymphoma following autoSCT include
chemoresistance, large tumor burden, short remission
duration, poor performance status, and extranodal
relapse [23,24]. Studies of children with lymphoma
treated with high-dose chemotherapy and autologous
stem cell rescue are limited by small numbers, and wide
variety of pretransplant chemotherapy, and conditioning
regimens. Overall, they demonstrate OS rates similar to
adults [18,25].
Bone marrow transplant (BMT) conditioning regi-
mens includingcyclophosphamide, carmustine (BCNU),
and etoposide (CBV), either as separate agents or
together are effective in adults with recurrent NHL
and HL [21,26-30]. This report describes the results
of a prospective study assessing the toxicity and
efficacy of CBV and autologous peripheral blood stem
cell transplantation (PBSCT) in pediatric patients with
relapsed or refractory lymphoma who achieve
a complete remission/partial remission (CR/PR) after
reinduction.PATIENTS AND METHODS
Study Eligibility for Entry onto Protocol
This prospective study enrolled children, initially
diagnosed between the ages of 12 months and 21 years,
at time of their first relapse or induction failure (defined
as failure to achieve a CR with a reinduction chemo-
therapy forHL, 2 cycles of a reinduction chemotherapy
for NHL, or 4 cycles for large cell lymphoma patients).
The study excluded patients with low-stageHL treated
with radiation only or with chemotherapy only, and
human immunodeficiency virus (HIV) positive
patients. Local institutional review boards approved
the study at each institution, and the patient or legal
guardians signed an informed consent.
Pathology
Study pathologists centrally reviewed patient
materials from initial diagnosis and relapse to confirmdi-
agnosis utilizing the Revised European American Lym-
phoma (REAL) classification. Six cases of large-cell
lymphoma had additional immunoperoxidase staining
using an automated immunostainer (Ventana, Tucson,
AZ)andheat-inducedepitoperetrievalwithamicrowave.
Lineage-specific stains included: anti-CD-20 (DAKO,
Carpenterial, CA) for B cell lineage, CD3 or CD45RO
(DAKO) for T cell lineage, and CD30 (DAKO) and
ALK-1 (DAKO) for anaplastic large-cell lymphoma
(ALCL).Criteria for Response and Relapse
No evidence of disease by physical exam and imag-
ing studies (computed tomography [CT] scan), includ-
ing negative BM and cerebrospinal fluid (CSF),
constituted a CR. A reduction in the total volume of
all measured lesions by at least 50% with no single
lesion increasing by.25% and no new lesions consti-
tuted a PR. Stable disease (SD) was defined as a reduc-
tion in the total volume of all measured lesions of
\50% with no single measured tumor lesion increas-
ing in volume by .25% and no new lesions. Failure
to achieve a CR with growth in any measured lesion
by .25% in volume, or development of new lesions
or new sites of tumor constituted progressive disease
(PD). Recurrence was defined as redevelopment of
tumor at any site after achievement of a CR.
Reinduction Chemotherapy
The protocol did not prescribe the reinduction
chemotherapy regimen. Among the HL (N 5 39)
patients, 13 received ifosfamide, carboplatin, etopo-
side (ICE) and 11 received vinorelbine and ifosfamide
(VI). Among the NHL patients (N 5 30), 17 received
ICE.
Eligibility for Stem Cell Collection
Patients completing 2 courses of reinduction
chemotherapy with at least SD and no evidence of
BM involvement proceeded to PBSC collection. Pa-
tients were mobilized following chemotherapy and
granulocyte-colony stimulating factor (G-CSF) ther-
apy and collected after hematologic recovery. Patients
not meeting response criteria after 2 courses received 2
additional courses of reinduction therapy. Patients
with persistent BM involvement after 4 cycles of rein-
duction therapy came off study.
PBSC Collection
Mobilization consisted of G-CSF 10 mg/kg daily
for at least 3 days prior to and on the days of apheresis.
The minimum goal of collection was 2  106 CD341
cells/kg and the target was 5  106 CD341 cells/kg.
PBSC harvesting used standard procedures on either
a COBE Spectra or Fenwall CS-3000 Plus apheresis
machine.
Eligibility for Autologous PBSCT
Patients in PR or CR after no more than 4 cycles of
reinduction chemotherapy and with adequate PBSC
stored proceeded toCBV conditioning and autologous
PBSCT. Patients with PD or SD were ineligible to
proceed. Patients going to transplant met the follow-
ing criteria of organ function: liver transaminsase
\2.5 normal, total bilirubin\1.5mg/dL, a glomeru-
lar filtration rate (GFR) of .60 mL/min/1.73 m2, and
a serum creatinine #1.5 mg/dL, a shortening fraction
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tion .50% of normal, and on pulmonary function
testing (PFTs) a vital capacity (VC) $65% and a total
lung capacity (TLC) $50% of normal.
Transplant Conditioning Regimen
All patients received cyclophosphamide 1800mg/m2/
day over 1 hour on days25,24,23,22, and etoposide
800 mg/m2/day over 24 hours on days28,27, and 26.
The first 6 patients received BCNU at 150 mg/m2/day
for 3 days and the remaining 32 patients received 100
mg/m2/day for 3 days on days28,27, and26, following
the amendment in February 2000 reducing the BCNU
dose.Protocol treatment includedMesna toprevent hem-
orrhagic cystitis. Patients received methylprednisolone as
a protective agent to reduce the risk of pulmonary toxicity
as follows: 1mg/kgdays29 to22, then taperedoff byday
16. All other supportive care was per local institutional
guidelines.
Hematopoietic Growth Factor Support
Patients received 5 mg/kg G-CSF over 2 hours af-
ter the infusion of the stem cells daily until the absolute
neutrophil count (ANC) was .2000/mm3 for 3 days.
Engraftment
The first of 3 days of an ANC of .500/mm3 and
a platelet count of.50,000/mm3withoutplatelet trans-
fusion defined neutrophil and platelet engraftment.
Follow-up After Transplant
Imaging at sites of disease occurred on days 128,
1100, 6 months, and 1, 2, 3, and 5 years after trans-
plant. Patients underwent PFTs at 3, 6, and 12 months
posttransplant. If PFTs were abnormal, patients
repeated them at 6month intervals until normalization
or stabilization.
Statistical Analysis
SAS software, Version 9.1 (SAS Institute, Cary,
NC) was used for statistical analysis. OS is the time
on study or transplant to death or last follow-up.
Relapse, progression, or death defined the events in
the EFS determination. EFS is the time from on study
or transplant to an event or last follow-up for those
who did not have an event. Toxicity was graded
according to the NCI CTCAE v. 2.0 common toxicity
scale. Descriptive statistics summarized demographic
and clinical variables. Chi-square tests were used to
compare response rates for HL and NHL. Fisher’s ex-
act test compared toxicity rates by BCNU dose. The
days to myeloid and platelet recovery, EFS, OS, and
time to relapse were determined by the method of
Kaplan-Meier. Patients who did not obtain recovery
were censored at first event or last follow-up following
transplant. The log-rank test compared time to eventdistributions between groups. Statistically significant
P-values were \.05. The above outcomes measures
were tested in the following subgroups: NHL versus
HL, nodular sclerosing HL versus other HL patients,
Burkitt’s (BL)/Burkitt like versus lymphoblastic NHL,
CR versus PR just prior to transplant, length of CR1
.1 year versus\1year, HL age .15years versus\15
years, relapse on or off therapy, failed induction versus
relapse, and the dose of BCNU. The effect of length
of CR1 was also separately tested in HL and NHL
patients.RESULTS
Patient Entry
Sixty-nine patients enrolled, 39 with HL and 30
withNHL. Thirty-eight patients received CBV condi-
tioning and autologous PBSCT; 28 with HL and 10
with NHL. Study investigators amended the protocol
on February 11, 2000, to reduce the dose of the BCNU
from 450 mg/m2 to 300 mg/m2.
Pretreatment Characteristics
The study entry patient characteristics for the HL
patients and the NHL patients are in Table 1. Four
HL patients entered for failed induction and 35 at
time of first relapse. Four NHL patients entered for
failed induction and 26 at time of first relapse.
Central Pathology Review
Forty-one patients (15 NHL, 26 HL) had pathol-
ogy material available for central classification of
histologic subtypes. The histologic subtypes of the
39 cases of HL and the 30 NHL are shown in Table 1.
Reinduction Efficacy
Of the 39HL patients, 30 achieved a CR/PR. Four
failed because of PD, 4 achieved only an SD status, and
1 was unevaluable. Among the 30 NHL patients, 13
achieved a CR/PR among the 26 patients evaluable
(4/8 with lymphoblastic lymphoma [LBL], 2/5 with
diffuse large B-cell lymphoma [DLCL], 4/5 with
ALCL, and 3/8 with BL). TenNHL patients failed be-
cause of PD, 3 achieved only an SD status, and 4 were
inevaluable. The NHL patients were less likely to
achieve CR/PR than the HL patients (45% versus
77%, P 5 .007). Overall, 43 of the 69 patients (62%)
achieved a CR/PR, and 38 (28 HL, 10 NHL) pro-
ceeded to transplant. Four patients refused to proceed
to CBV conditioning and autoSCT (Figure 1).
Autologous Collection and Hematopoietic
Recovery
Fifty-one patients underwent PBSC apheresis; 40
successfully obtained adequate stem cells for transplant
Table 1. Characteristics of the Patients
Characteristic HL Patients N 5 39 NHL Patients N 5 30
Age at diagnosis, median (range), years 14.5 (5.3-20.4) 12.8 (4.2-19.9)
Male sex, no. (%) 19 (49%) 21 (70%)
Race, no. (%)
White, non-Hispanic 29 (74%) 24 (80%)
Black, non-Hispanic 2 (5%) 4 (13%)
Hispanic 6 (15%)
Filipino/Asian 1 (3%) 1 (3%)
Unknown 1 (3%) 1 (3%)
HL histologic subtype, no. (%)
Mixed Cellularity, NOS 1 (3%) N/A
Nodular sclerosis (NS) 34 (87%) N/A
NOS 4 (10%) N/A
NHL histologic subtype, no. (%)
Large cell lymphoma N/A 5 (17%)
Anaplastic large cell lymphoma N/A 5 (17%)
Lymphoblastic lymphoma N/A 8 (27%)
Burkitt’s N/A 7 (23%)
Burkitt-like (non-Burkitt’s) N/A 4 (13%)
Unknown N/A 2 (7%)
Months from diagnosis to relapse, median (range) 12.0 (1.9-63.8) 7.9 (1.6-52.6)
Age at relapse, median (range), years 16.1 (5.7-22.4) 13.5 (5.1-20.2)
Stage at relapse, no. (%)
I 3 (8%) 3 (10%)
III 23 (59%) 20 (67%)
IV 13 (33%) 6 (20%)
Unknown 1 (3%)
Mediastinum involvement at relapse, no. (%) 23 (59%) N/A
Reinduction therapy, no. (%)
ICE 13 (33%) 17 (57%)
VI 11 (28%) N/A
Other 15 (38%) 12 (40%)
Unknown 1 (3%)
NS indicates nodular sclerosing; MC, mixed cellularity; LD, lymphocyte depleted; NOS, not otherwise specified; ICE, ifosfamide, carboplatin, etoposide;
VI, vinorelbine, ifosfamide; HL, hodgkin lymphoma; NHL, non-hodgkin lymphoma.
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stored was 6.2  106/kg (range 0.2  106 to 94.7 
106/kg). The median cell dose infused was 6 
106CD341/kg. The myelogenous engraftment rates for
anANCof 500/mm3or 1000/mm3were not significantly
different based on CD341/kg cell dose. However, theFigure 1. Flow diagram of patients from diagnosis and study entry, fol-
lowing reinduction, autologous PBSCT, and final outome.median time to recover the platelet count of 50,000/
mm3 was significantly improved with a higher CD
341/kg cell dose ([.4  106/kg versus #4  106CD
341/kg] {20 [4-48 days] versus 41 [39-480 days]}). There
was no significant difference in the engraftment kinetics
between the HL versus the NHL patients.
Toxicity and Treatment-Related Mortality
(TRM) Following CBV Conditioning and
Autologous Transplantation
All 6 patients receiving 450mg/m2 of BCNUdevel-
oped grade III or IV pulmonary toxicity with onset
between 30 to 60 days posttransplant. Four of the 6
required supplemental oxygen (duration 5 days to
9 months) and 5 received steroids. All but 2 came off
supplemental oxygen therapy after a few days. One
patient developed persistent abnormal PFTs, but
came off oxygen after 9 months. The other patient re-
lapsed 6 months after transplant while still on steroids
and oxygen.None of the subsequent 32 patients treated
with 300 mg/m2 of BCNU developed grade III or IV
pulmonary toxicity (P\.0001).
EFS and OS
The median follow-up from date of study entry
of the survivors is 3.2 years (maximum 6.3 years).
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51% (95% confidence interval [CI], 38%-62%)
(Figure 2A). The 3-year OS from date of study entry
for HL patients is 63% (95% CI, 46%-76%) and for
NHL patients is 34% (95% CI, 17%-52%)
(Figure 2B) (HL versus NHL: P 5 .0087). The 3-
year EFS of all 69 patients from study entry is 38%
(95% CI, 27%-50%) (Figure 3A). The 3-year EFS
from study entry for HL patients is 45% (95% CI,
29%-60%) and for NHL patients is 30% (95% CI,
15%-46%) (HL versus NHL: P 5 .015) (Figure 3B).
EFS and OS by response to reinduction
chemotherapy
Patients achieving a CR/PR versus SD/PD had
significantly better OS and EFS at 3 years: OS 73%
versus 6%, P \.001 (Figure 4A); EFS 54% versusFigure 2. (A) OS of all patients from date of relapse or progressive disease cal
of relapse or progressive disease in HL versus NHL patients calculated by the10%, P\.001 (Figure 4B). This analysis excludes 5 pa-
tients inevaluable for response because of early death
from toxicity or infection. EFS and OS were similar
in those patients who achieved a CR versus PR follow-
ing reinduction chemotherapy.
Outcome after transplant
Overall, 26 of the 38 patients who underwent CBV
conditioning and autologousPBSCTsurvived: 20 of 26
are progression free (14 HL, 6 NHL). The 3-year OS
from transplant is 64% (95% CI, 45%-78%) (HL
64%, 95% CI, 41%-80%; NHL 70%, 95% CI, 33%-
89%). The 3-year EFS from transplant is 66% (95%
CI, 48%-79%) (HL 65%, 95% CI, 43%-80%; NHL
70%, 95%CI, 33%-80%) (HL versus NHL: P5NS).
The median time to relapse after CBV condition-
ing and autologous PBSCT for HL patients was 0.6culated by the method of Kaplan-Meier. (B) Comparison of OS from time
method of Kaplan-Meier.
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was 0.1 year (0.1-0.2 years). Twelve patients died after
PBSCT: 7 from PD, 4 from infection, and 1 from tox-
icity. There was no difference in efficacy between the
450 mg/m2 BCNU dose and the 300 mg/m2 BCNU
dose.
EFS and OS by Length of First Remission
The median length of first remission was 11.7
months. EFS and OS were determined for all patients
from study entry and from the date of PBSCT for those
with a short (\12 months) versus a longer first remis-
sion ($12months).Fromstudyentry, therewasa signif-Figure 3. (A) EFS of all patients from date of relapse or progressive disease cal
of relapse or progressive disease in HL versus NHL patients calculated by theicant increase in OS in patients with an initial CR$ 12
versus \12 months (3 years OS 70% versus 34%,
P 5 .003) (Figure 5). EFS was only marginally better
with length of CR $12 months versus shorter
(P 5 .05). This difference was only evident in HL
patients (OS: P\.001, EFS: P 5 .007) (NHL patients
(OS: P5 .37, EFS: P5 .71).DISCUSSION
Themajor finding of this study is that 300mg/m2 of
BCNU within a CBV conditioning regimen prior to
autologous PBSCT is well tolerated by children withculated by the method of Kaplan-Meier. (B) Comparison of EFS from time
method of Kaplan-Meier.
Figure 4. (A) Comparison of OS from date of relapse or progressive disease in patients achieving a CR/PR versus SD/PD following reinduction cal-
culated by the method of Kaplan-Meier. All patients were included except those who were inevaluable for response because of early toxic or infectious
death (n 5 5). (B) Comparison of EFS from date of relapse or progressive disease in patients achieving a CR/PR versus SD/PD following reinduction
calculated by the method of Kaplan-Meier. All patients were included except those who were inevaluable for response because of early toxic or infec-
tious death (n 5 5).
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BCNU was associated with unacceptable pulmonary
toxicity. Five of the 6 patients who developed pulmo-
nary toxicity in this study also received mantle irradia-
tion around the time of CBV conditioning and
autologous PBSCT. Reece and others [28,30-32] first
described pulmonary toxicity in patients receiving 600
mg/m2 of BCNU and irradiation. Subsequent studies
in adults using either 450 mg/m2 or 300 mg/m2 of
BCNU reported less pulmonary toxicity [20,31,32].The BCNU dose of 300 mg/m2 was not associated
with any reduction in efficacy.
The efficacy of CBV conditioning in this pediatric
study is comparable to that demonstrated in studies of
adults. Reece et al. [28] reported 5-year OS and EFS
rates of 53% and 47% using a BCNU dose of 600
mg/m2 in CBV and autologous PBSCT in 56 relapsed
HL patients. Using 300 mg/m2 BCNU in a CBV con-
ditioning regimen resulted in 5-year OS and failure
free rates of 51% and 40%, respectively [28]. Brice
Figure 5. Comparison of OS from date on study (all patients) in patients with first remission\12 months versus patients with first remission $12
months calculated by the method of Kaplan-Meier.
256 Biol Blood Marrow Transplant 17:249-258, 2011R. E. Harris et al.et al. [33] reported OS and progression-free survival
(PFS) rates at 4 years of 66% and 60%, respectively,
in 280 patients undergoing myeloablative conditioning
and autologous BMT for relapsed HL. The largest se-
ries of autoSCT in adult NHL patients with aggressive
histologies demonstrated a 43%5-yearOS and relapse-
free survival (RFS) [19]. Poor prognostic factors in
adults include “B” symptoms, extranodal disease, dura-
tion of first remission, and chemosensitivity [28,30,33].
We confirmed that chemosensitivity in children and
adolescents with relapsed NHL and HL following
reinduction therapy was associated with a better
outcome for children with both HL and NHL, but
a duration of first remission was only significant in
predicting outcome in children with recurrent HL.
Studies inpediatric patients are confoundedby small
numbers and a mixture of patients receiving autologous
transplant and allogeneic transplant [25]. However, this
is the first pediatric prospective autologous SCT study
reported that follows the outcome of patients from the
time of relapse, induction failure, or progression and
not just at the time of conditioning and autologous
SCT. This is of critical importance because most au-
toSCT results only report outcomes from the time con-
ditioning starts and not the time from disease relapse/
progression. Our study notes that only 62% of patients
achieved aCR/PRafter reinduction therapy andwere el-
igible for CBV conditioning and autologous PBSCT
and 90% of those patients proceeded to autoSCT. For
recurrent HL in pediatric patients, a report by Verde-
guer et al. [34] from the Spanish Pediatric BMTGroup
reported on 20 children with relapsed or refractory HL
who underwent autologous BMT; 18 with CBV (cyclo-
phosphamide6000mg/m2,BCNU300mg/m2, and eto-
posideof 1000mg/m2).Mostwere inCR2orgreater and
14of 18hadprior irradiation.Among all 20 children, the
5-yearOS andEFSwas 95%and 62%, respectively [34].
Four of 5 children who relapsed posttransplant weresuccessfully salvaged.Only 1 death occurred from trans-
plant related causes. The only pulmonary toxicity was
pneumonia and the transplant regimens were well toler-
ated [34]. For recurrent NHL in pediatric patients,
Bureo et al. [35] reported on 46 children with relapsed
NHLwho underwent a transplant (14 allogeneic, 32 au-
tologous) including 21 children with LBL, 19 with BL,
and 6 with large cell lymphoma (LCL). In this study
where all patients were at least a CR2, 13 of the children
received transplant in first CR, 9 because of prolonged
time to achieveCRor failure of frontline therapy. Over-
all EFSwas 58%with amedian follow-up of 33months.
EFS was similar for autologous and allogeneic recipi-
ents. The only factor which predicted outcome was
disease status at BMT (CR1 versusCR2 versusCR3 ver-
sus more advanced disease) [35]. Brugieres et al. [36]
reported that myeloablative therapy and autologous
SCT for children with relapsed ALCL is dismal in
patients with early relapse (28% 3 year EFS).
Of patients achieving a CR/PR, autologous PBSC
apheresis was successful in 89% of the children and
adolescents on this trial in achieving an adequate
CD341/kg cell yield. Engraftment results in the cur-
rent study is consistent with other reported studies in-
volving myeloablaitve conditioning and autologous
PBSCT [34].
The weaknesses of this study include a lack of
consistent reinduction regimen and small numbers of
patients with NHL who were eligible to proceed
to CBV conditioning and autologous PBSCT either
from lack of response to reinduction therapy or re-
fusal. Most HL patients received either ICE or a com-
bination of VI. Most NHL patients received ICE.
Surprisingly, our reinduction efficacy in patients with
LBL is higher than expected but the numbers are
quite small [37].
The high rate of posttransplant relapse in this
study is potentially because of 2 mechanisms: tumor
Biol Blood Marrow Transplant 17:249-258, 2011 257PBSCTwith CBV for Pediatric Lymphomascells in the PBSC product, and/or inadequate disease
control using cytotoxic agents. It is generally accepted
that autologous PBSC are less likely to be contami-
nated with tumor cells than BM. PBSC were not
collected until patients achieved a CR/PR/SD with
negative BM disease, which potentially reduced the
risk of tumor cell contamination.
New approaches are needed to improve the EFS
reported in our study. Reinduction therapy, especially
for NHL patients, is not adequate. Salvage therapy
might be improved by the addition of rituximab
(anti-CD20 monoclonal antibody) in patients with
B cell disease (COG ANHL0121) [38]. The addition
of anti-T cell or anti CD-30 monoclonal antibodies
or other targeted therapy in patients with T-lympho-
blastic lymphoma, ALCL, or HL may improve the
reinduction rate. The use of monoclonal antibodies
or other therapies post-BMT might also reduce the
relapse rate [39,40]. Improved conditioning regimens
using conventional chemotherapy agents prior to
autologous transplant are unlikely to significantly
affect outcome [34]. However, there is considerable
emerging evidence of a graft-versus-lymphoma effect
following allogeneic SCT [41-46]. There may be
benefit from combining autologous PBSCT with
reduced intensity allogeneic transplantation to add
graft-versus-lymphoma effects after cytoreduction
[47]. Pilot studies using CBV and autologous PBSCT
followed by reduced intensity allogeneic BMT
show promise in children with high-risk lymphoma
[25,48]. A larger cohort with a longer follow-up is
required to determine the feasibility of these ap-
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